[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"7d41bb5c-8775-4bbb-9bda-315d6ca7d0d0","acronym":"SELECT-2","url":"https://clinicaltrials.gov/study/NCT04401059","created_at":"2023-12-27T18:16:50.631Z","updated_at":"2024-07-02T16:35:25.073Z","phase":"Phase 4","brief_title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","source_id_and_acronym":"NCT04401059 - SELECT-2","lead_sponsor":"Tian Xie","biomarkers":" EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR positive","tags":["EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 744","initiation":"Initiation: 11/09/2020","start_date":" 11/09/2020","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2023-12-27"},{"id":"d03b8b45-8a6a-456f-a325-777a68fe67a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05263947","created_at":"2022-03-03T14:06:10.362Z","updated_at":"2024-07-02T16:35:57.562Z","phase":"Phase 2","brief_title":"Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation","source_id_and_acronym":"NCT05263947","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Conmana (icotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/30/2021","start_date":" 08/30/2021","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2023-01-16"},{"id":"2a170240-672b-4940-9a07-7f07449fbc2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05514314","created_at":"2022-08-24T21:07:49.992Z","updated_at":"2024-07-02T16:36:04.962Z","phase":"Phase 2","brief_title":"A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection","source_id_and_acronym":"NCT05514314","lead_sponsor":"Wu Nan","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Conmana (icotinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2022-08-24"},{"id":"47df1c56-d2c2-46e3-8396-615e883ce346","acronym":"CORIN","url":"https://clinicaltrials.gov/study/NCT02264210","created_at":"2021-01-18T10:38:21.136Z","updated_at":"2024-07-02T16:36:27.042Z","phase":"Phase 2","brief_title":"Icotinib for Completed Resected IB NSCLC With EGFR Mutation","source_id_and_acronym":"NCT02264210 - CORIN","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Conmana (icotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2021-08-03"},{"id":"d1aba1a3-a8e4-4546-9ddb-fc3c5b485cc5","acronym":"EVIDENCE","url":"https://clinicaltrials.gov/study/NCT02448797","created_at":"2021-01-18T11:44:26.884Z","updated_at":"2024-07-02T16:36:27.683Z","phase":"Phase 3","brief_title":"Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation","source_id_and_acronym":"NCT02448797 - EVIDENCE","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • Conmana (icotinib) • vinorelbine tartrate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 06/08/2015","start_date":" 06/08/2015","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2021-07-20"},{"id":"634607b4-2c69-48ef-a65c-41849aa77e8a","acronym":"SAINT","url":"https://clinicaltrials.gov/study/NCT04797806","created_at":"2021-03-23T07:14:20.515Z","updated_at":"2024-07-02T16:36:33.327Z","phase":"Phase 3","brief_title":"Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC","source_id_and_acronym":"NCT04797806 - SAINT","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Conmana (icotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 206","initiation":"Initiation: 03/12/2021","start_date":" 03/12/2021","primary_txt":" Primary completion: 04/30/2022","primary_completion_date":" 04/30/2022","study_txt":" Completion: 04/30/2023","study_completion_date":" 04/30/2023","last_update_posted":"2021-03-15"},{"id":"d2e15d38-008c-41a2-a740-631f6ffd89e1","acronym":"ALTER-L004","url":"https://clinicaltrials.gov/study/NCT03736837","created_at":"2021-01-17T17:24:29.848Z","updated_at":"2024-07-02T16:36:33.338Z","phase":"Phase 2","brief_title":"Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC","source_id_and_acronym":"NCT03736837 - ALTER-L004","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Conmana (icotinib)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2021-03-15"},{"id":"543b504f-ea6d-4074-8107-d26ea7d2759a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02737774","created_at":"2021-01-18T13:24:33.582Z","updated_at":"2024-07-02T16:36:43.698Z","phase":"Phase 2","brief_title":"Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation","source_id_and_acronym":"NCT02737774","lead_sponsor":"Henan Cancer Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Conmana (icotinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 04/13/2016","start_date":" 04/13/2016","primary_txt":" Primary completion: 10/25/2019","primary_completion_date":" 10/25/2019","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2020-07-01"},{"id":"2c6f6b05-a1a5-43a4-b9e0-35447e4fc147","acronym":"SMART","url":"https://clinicaltrials.gov/study/NCT04058704","created_at":"2021-01-18T19:53:20.813Z","updated_at":"2024-07-02T16:36:56.864Z","phase":"Phase 3","brief_title":"A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy","source_id_and_acronym":"NCT04058704 - SMART","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Conmana (icotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 296","initiation":"Initiation: 07/20/2018","start_date":" 07/20/2018","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2019-08-15"},{"id":"50e76ca4-b76c-49d8-8ddd-52aba628c34c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04007835","created_at":"2021-01-18T19:41:37.452Z","updated_at":"2024-07-02T16:36:58.359Z","phase":"","brief_title":"Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI","source_id_and_acronym":"NCT04007835","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib • Focus V (anlotinib) • Conmana (icotinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2019-07-05"},{"id":"850ae188-410a-4e4d-a744-bf936a798cb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01855854","created_at":"2021-01-18T08:17:20.925Z","updated_at":"2024-07-02T16:36:58.374Z","phase":"Phase 2","brief_title":"Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH","source_id_and_acronym":"NCT01855854","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Conmana (icotinib)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 01/07/2016","study_completion_date":" 01/07/2016","last_update_posted":"2019-07-05"},{"id":"98b49979-d002-45be-bd3d-44a1a8ac61c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01719536","created_at":"2021-01-18T07:29:59.054Z","updated_at":"2024-07-02T16:36:58.434Z","phase":"Phase 3","brief_title":"Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients","source_id_and_acronym":"NCT01719536","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • Conmana (icotinib)"],"overall_status":"Completed","enrollment":" Enrollment 296","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 02/07/2017","study_completion_date":" 02/07/2017","last_update_posted":"2019-07-05"},{"id":"5c5b12d5-406a-4ca7-97de-ed17104be397","acronym":"","url":"https://clinicaltrials.gov/study/NCT03992885","created_at":"2021-01-18T19:37:48.076Z","updated_at":"2024-07-02T16:36:58.766Z","phase":"Phase 3","brief_title":"Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.","source_id_and_acronym":"NCT03992885","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Conmana (icotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2019-06-20"},{"id":"e62aafa3-6488-4c88-9548-4773f984e3bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02726568","created_at":"2021-01-18T13:20:46.901Z","updated_at":"2024-07-02T16:37:02.658Z","phase":"Phase 2","brief_title":"High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases","source_id_and_acronym":"NCT02726568","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Conmana (icotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2019-02-19"},{"id":"31b33390-0e4f-4959-a81c-a1f3e407f7c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03766490","created_at":"2021-01-18T18:38:14.785Z","updated_at":"2024-07-02T16:37:03.392Z","phase":"","brief_title":"Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03766490","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • Focus V (anlotinib) • Conmana (icotinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 66","initiation":"Initiation: 03/30/2019","start_date":" 03/30/2019","primary_txt":" Primary completion: 12/20/2019","primary_completion_date":" 12/20/2019","study_txt":" Completion: 12/20/2020","study_completion_date":" 12/20/2020","last_update_posted":"2019-01-30"},{"id":"28345d06-c1e7-468c-8401-00faaab1096f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03749213","created_at":"2021-01-18T18:23:03.830Z","updated_at":"2024-07-02T16:37:05.133Z","phase":"Phase 2","brief_title":"Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03749213","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Conmana (icotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2018-11-21"},{"id":"fd5c192c-735b-49b3-81a7-a818b83a3a81","acronym":"secgolc004","url":"https://clinicaltrials.gov/study/NCT03720873","created_at":"2021-01-17T17:11:56.928Z","updated_at":"2024-07-02T16:37:05.799Z","phase":"Phase 2","brief_title":"EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC","source_id_and_acronym":"NCT03720873 - secgolc004","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 21 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 21 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib • Focus V (anlotinib) • Conmana (icotinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 90","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 09/01/2022","study_completion_date":" 09/01/2022","last_update_posted":"2018-10-25"},{"id":"e03dfb61-7d3d-4e96-b360-76b8343a9fd2","acronym":"ICTAN","url":"https://clinicaltrials.gov/study/NCT01996098","created_at":"2021-01-18T09:06:22.651Z","updated_at":"2024-07-02T16:37:07.423Z","phase":"Phase 3","brief_title":"Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation","source_id_and_acronym":"NCT01996098 - ICTAN","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Conmana (icotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2018-08-28"},{"id":"2f6fe6a4-4a85-4df1-bf19-c03b74f61a17","acronym":"","url":"https://clinicaltrials.gov/study/NCT03396185","created_at":"2021-01-18T16:45:35.087Z","updated_at":"2024-07-02T16:37:08.863Z","phase":"Phase 2","brief_title":"Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03396185","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Conmana (icotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/09/2018","start_date":" 05/09/2018","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 02/01/2023","study_completion_date":" 02/01/2023","last_update_posted":"2018-07-18"},{"id":"3327b24a-b5a2-42fc-9f92-c109e12ce316","acronym":"","url":"https://clinicaltrials.gov/study/NCT03349203","created_at":"2021-01-18T16:32:19.125Z","updated_at":"2024-07-02T16:37:08.898Z","phase":"Phase 2","brief_title":"Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03349203","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Conmana (icotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2018-07-18"},{"id":"e481799c-927c-4f30-8f18-11857100274c","acronym":"ICWIP","url":"https://clinicaltrials.gov/study/NCT02125240","created_at":"2021-01-18T09:50:45.000Z","updated_at":"2024-07-02T16:37:08.952Z","phase":"Phase 3","brief_title":"Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma","source_id_and_acronym":"NCT02125240 - ICWIP","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Conmana (icotinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 124","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 07/01/2021","study_completion_date":" 07/01/2021","last_update_posted":"2018-07-16"},{"id":"29d2913f-2365-4a19-be6f-7ee47aba0e62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03151161","created_at":"2021-01-18T15:31:55.324Z","updated_at":"2024-07-02T16:37:10.227Z","phase":"Phase 2","brief_title":"Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation","source_id_and_acronym":"NCT03151161","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Conmana (icotinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 118","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2018-06-07"},{"id":"726ffc07-106e-4044-9f56-0ddb6dd2b788","acronym":"","url":"https://clinicaltrials.gov/study/NCT01534585","created_at":"2021-01-18T06:28:37.482Z","updated_at":"2024-07-02T16:37:11.511Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT01534585","lead_sponsor":"Taizhou Hospital","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Conmana (icotinib)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 02/01/2013","primary_completion_date":" 02/01/2013","study_txt":" Completion: 02/01/2015","study_completion_date":" 02/01/2015","last_update_posted":"2018-04-17"}]